ANGIOTENSIN RECEPTOR-NEPRILYSIN INHIBITOR SUPPRESSED CARDIAC DYSFUNCTION BY ANGIOGENESIS IN MICE MODEL OF ATHEROSCLEROSIS. (April 2021)
- Record Type:
- Journal Article
- Title:
- ANGIOTENSIN RECEPTOR-NEPRILYSIN INHIBITOR SUPPRESSED CARDIAC DYSFUNCTION BY ANGIOGENESIS IN MICE MODEL OF ATHEROSCLEROSIS. (April 2021)
- Main Title:
- ANGIOTENSIN RECEPTOR-NEPRILYSIN INHIBITOR SUPPRESSED CARDIAC DYSFUNCTION BY ANGIOGENESIS IN MICE MODEL OF ATHEROSCLEROSIS
- Authors:
- Suematsu, Yasunori
Ideishi, Akihito
Tashiro, Kohei
Miura, Shin-Ichiro - Abstract:
- Abstract: Objective: We previously reported that Angiotensin receptor-neprilysin inhibitor (ARNI) has the effects of suppression of myocardial hypertrophy and fibrosis in addition to reduction of afterload by natriuretic effect. We investigated the effects of ARNI against mice model of atherosclerosis. Design and method: Atherosclerotic model was induced by high cholesterol diet for 4 weeks to apolipoprotein E knockout mice. We divided into four groups: no treatment (CTL), valsartan 30 mg/kg (VAL), sacubitril (neprilysin inhibitor) 30 mg/kg (SAC), and ARNI 60 mg/kg for additional 13 weeks. Results: Body weight and systolic blood pressure in the VAL, SAC and ARNI groups did not show significant differences compared to those in the CTL group. Serum brain natriuretic peptide (BNP) in ARNI group (605 ± 221 pg/ml) was significantly increased than that in VAL (391 ± 57 pg/ml) and SAC (357 ± 91 pg/ml) groups, but not CTL group (393 ± 192 pg/ml). Although the rate of atherosclerotic area in aorta was 16.3 ± 5.8 % after treatment, there were no significant differences between the groups. In the CTL group, left ventricular ejection fraction (LVEF, 81.6 ± 4.8 %) and fractional shortening (FS, 44.8 ± 5.8 %) at baseline were significantly reduced after treatment (67.8 ± 8.2 % and 33.3 ± 6.1 %). Interestingly, LVEF (76.6 ± 6.7 %) and FS (40.1 ± 6.1 %) after treatment in the ARNI group were significantly preserved compared to those in the CTL group. In real time polymerase chain reactionAbstract: Objective: We previously reported that Angiotensin receptor-neprilysin inhibitor (ARNI) has the effects of suppression of myocardial hypertrophy and fibrosis in addition to reduction of afterload by natriuretic effect. We investigated the effects of ARNI against mice model of atherosclerosis. Design and method: Atherosclerotic model was induced by high cholesterol diet for 4 weeks to apolipoprotein E knockout mice. We divided into four groups: no treatment (CTL), valsartan 30 mg/kg (VAL), sacubitril (neprilysin inhibitor) 30 mg/kg (SAC), and ARNI 60 mg/kg for additional 13 weeks. Results: Body weight and systolic blood pressure in the VAL, SAC and ARNI groups did not show significant differences compared to those in the CTL group. Serum brain natriuretic peptide (BNP) in ARNI group (605 ± 221 pg/ml) was significantly increased than that in VAL (391 ± 57 pg/ml) and SAC (357 ± 91 pg/ml) groups, but not CTL group (393 ± 192 pg/ml). Although the rate of atherosclerotic area in aorta was 16.3 ± 5.8 % after treatment, there were no significant differences between the groups. In the CTL group, left ventricular ejection fraction (LVEF, 81.6 ± 4.8 %) and fractional shortening (FS, 44.8 ± 5.8 %) at baseline were significantly reduced after treatment (67.8 ± 8.2 % and 33.3 ± 6.1 %). Interestingly, LVEF (76.6 ± 6.7 %) and FS (40.1 ± 6.1 %) after treatment in the ARNI group were significantly preserved compared to those in the CTL group. In real time polymerase chain reaction analysis of LV after treatment, relative mRNA expression of BNP and angiogenetic factors including ATPase sarcoplasmic/endoplasmic reticulum Ca transporting 2, vascular endothelial growth factor A, cluster of differentiation 34 in ARNI group were significantly increased than those in the CTL group. Conclusions: Although ARNI did not suppress atherosclerosis in mice, it preserved LVEF via improving angiogenetic ability. … (more)
- Is Part Of:
- Journal of hypertension. Volume 39(2021)e-Supplement 1
- Journal:
- Journal of hypertension
- Issue:
- Volume 39(2021)e-Supplement 1
- Issue Display:
- Volume 39, Issue 1 (2021)
- Year:
- 2021
- Volume:
- 39
- Issue:
- 1
- Issue Sort Value:
- 2021-0039-0001-0000
- Page Start:
- Page End:
- Publication Date:
- 2021-04
- Subjects:
- Hypertension -- Periodicals
Hypertension -- Periodicals
616.132005 - Journal URLs:
- http://firstsearch.oclc.org ↗
http://journals.lww.com/jhypertension/pages/default.aspx ↗
http://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=toc&D=yrovft&AN=00004872-000000000-00000 ↗
http://www.jhypertension.com/ ↗
http://journals.lww.com/pages/default.aspx ↗ - DOI:
- 10.1097/01.hjh.0000746572.65667.fd ↗
- Languages:
- English
- ISSNs:
- 1473-5598
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5004.510000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 19887.xml